Recombinant factor IX for clinical and research use

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 5, 2010, Pages 498-509

  Monahan, Paul E ^a,b   Di Paola, Jorge ^c  

^a Gene Therapy Center   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Factor IX; hemophilia B; hemostasis; recombinant

Indexed keywords

RECOMBINANT FACTOR IX; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 9;

CLINICAL TRIAL; COLUMN CHROMATOGRAPHY; COMPARATIVE EFFECTIVENESS; DIAFILTRATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG SAFETY; GENE MUTATION; HEMOPHILIA B; HUMAN; NONHUMAN; PREFORMULATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMBINANT DNA TECHNOLOGY; REVIEW; SITE DIRECTED MUTAGENESIS; SUBSTITUTION THERAPY; ULTRAFILTRATION; ANIMAL;

ANIMALS; FACTOR IX; HEMOPHILIA B; HUMANS; RECOMBINANT PROTEINS;

EID: 77954874075     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1255444     Document Type: Review

References (90)

1. Pavlovsky A. Contribution to the pathogenesis of hemophilia. Blood 1947 2 (2) 185-191
2. Biggs R, Douglas A S., MacFarlane R G., Dacie J V., Pitney W R., Merskey. Christmas disease: a condition previously mistaken for haemophilia. Br Med J 1952 2 (4799) 1378-1382
3. Aggeler P M., White S G., Glendening M B., Page E W., Leake T B., Bates G. Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia. Proc Soc Exp Biol Med 1952 79 (4) 692-694
4. Kurachi K, Davie E W. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A 1982 79 (21) 6461-6464
5. Choo K H., Gould K G., Rees D J., Brownlee G G. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982 299 (5879) 178-180
6. Toole J J., Knopf J L., Wozney J M. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984 312 (5992) 342-347
7. Yoshitake S, Schach B G., Foster D C., Davie E W., Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985 24 (14) 3736-3750 (Pubitemid 15011912)
8. Johnson I S. Human insulin from recombinant DNA technology. Science 1983 219 (4585) 632-637
9. White G C. II, Pickens E M., Liles D K., Roberts H R. Mammalian recombinant coagulation proteins: structure and function. Transfus Sci 1998 19 (2) 177-189
10. Evatt B L. The tragic history of AIDS in the hemophilia population, 19821984. J Thromb Haemost 2006 4 (11) 2295-2301
11. Kaufman R J., Wasley L C., Furie B C., Furie B, Shoemaker C B. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986 261 (21) 9622-9628
12. Chorba T L., Holman R C., Clarke M J., Evatt B L. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001 66 (4) 229-240
13. Pipe S W. Recombinant clotting factors. Thromb Haemost 2008 99 (5) 840-850
14. Stafford D W. The vitamin K cycle. J Thromb Haemost 2005 3 (8) 1873-1878
15. Harrison S, Adamson S, Bonam D et al. The manufacturing process for recombinant factor IX. Semin Hematol 1998 35 (2, Suppl 2) 4-10
16. Lambert T, Recht M, Valentino L A. et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007 13 (3) 233-243
17. Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998 35 (2, Suppl 2) 11-17
18. Wallmark A, Kunkel G, Mouhli H et al. Population genetics of the Malmö polymorphism of coagulation factor IX. Hum Hered 1991 41 (6) 391-396
19. Gillis S, Furie B C., Furie B et al. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci 1997 6 (1) 185-196
20. Kaufman R J. Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost 1998 79 (6) 1068-1079
21. Atoda H, Yokota E, Morita T. Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX. J Biol Chem 2006 281 (14) 9314-9320
22. White G C. II, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997 78 (1) 261-265
23. Arruda V R., Hagstrom J N., Deitch J et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001 97 (1) 130-138
24. Chang J-Y, Brock J, Griffith M J., Monroe D M. Glycosylation of the activation peptide of factor IX determines plasma half-life. J Thromb Haemost 2007 5 Abstract O-M-088
25. Begbie M E., Mamdani A, Gataiance S et al. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Thromb Haemost 2005 94 (6) 1138-1147
26. Bharadwaj D, Harris R J., Kisiel W, Smith K J. Enzymatic removal of sialic acid from human factor IX and factor X has no effect on their coagulant activity. J Biol Chem 1995 270 (12) 6537-6542
27. Fischer B E., Dorner F. Recombinant coagulation factor IX: glycosylation analysis and in vitro conversion into human-like sialylation pattern. Thromb Res 1998 89 (3) 147-150
28. Griffith M J., Monroe D M., Van Cott K E., Walker A, Waugh S, Drohan W N. N-Glycan sialylation is important for in vivo recovery of recombinant factor IX. J Thromb Haemost 2007 5 Abstract P-M-043
29. Sun Y M., Jin D Y., Camire R M., Stafford D W. Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X. Blood 2005 106 (12) 3811-3815
30. Wajih N, Hutson S M., Owen J, Wallin R. Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle. J Biol Chem 2005 280 (36) 31603-31607
31. Wajih N, Owen J, Wallin R. Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection. Thromb Res 2008 122 (3) 405-410
32. Noyes C M., Griffith M J., Roberts H R., Lundblad R L. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145. Proc Natl Acad Sci U S A 1983 80 (14) 4200-4202
33. Stanley T B., Wu S M., Houben R J., Mutucumarana V P., Stafford D W. Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. Biochemistry 1998 37 (38) 13262-13268
34. Stern D M., Drillings M, Nossel H L., Hurlet-Jensen A, LaGamma K S., Owen J. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci U S A 1983 80 (13) 4119-4123
35. Heimark R L., Schwartz S M. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun 1983 111 (2) 723-731
36. Toomey J R., Smith K J., Roberts H R., Stafford D W. The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain. Biochemistry 1992 31 (6) 1806-1808
37. Cheung W F., Hamaguchi N, Smith K J., Stafford D W. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992 267 (29) 20529-20531
38. Cheung W F., van den Born J, Kühn K, Kjellén L, Hudson B G., Stafford D W. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A 1996 93 (20) 11068-11073
39. Gui T, Lin H F., Jin D Y. et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002 100 (1) 153-158
40. Schuettrumpf J, Herzog R W., Schlachterman A, Kaufhold A, Stafford D W., Arruda V R. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005 105 (6) 2316-2323
41. Gui T, Reheman A, Ni H et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost 2009 7 (11) 1843-1851
42. Monahan P E., Liesner R, Sullivan S T., Ramirez M E., Kelly P, Roth D A. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010 16 460-468
43. Roth D A., Kessler C M., Pasi K J., Rup B, Courter S G., Tubridy K L., Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001 98 (13) 3600-3606
44. Shapiro A D., Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005 105 (2) 518-525
45. Poon M C., Lillicrap D, Hensman C, Card R, Scully M F. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002 87 (3) 431-435
46. Björkman S, Shapiro A D., Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001 7 (2) 133-139
47. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007 13 (1) 2-8
48. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998 35 (2, Suppl 2) 33-38
49. Ragni M V., Pasi K J., White G C., Giangrande P L., Courter S G., Tubridy K L., Recombinant FIX Surgical Study Group. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002 8 (2) 91-97
50. Ljung R C. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995 94 (Suppl 1) 49-52
51. Warrier I, Ewenstein B M., Koerper M A. et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997 19 (1) 23-27
52. Gouw S C., van den Berg H M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009 35 (8) 723-734
53. Chitlur M, Warrier I, Rajpurkar M, Lusher J M. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (19972006). Haemophilia 2009 15 (5) 1027-1031
54. Ewenstein B M., Takemoto C, Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997 89 (3) 1115-1116
55. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007 138 (3) 305-315
56. Dimichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009 15 (1) 320-328
57. The Universal Data Collection Program. Report on the Universal Data Collection Program. July 2005; 7(1). Available at: http://www.cdc.gov/ncbddd/ hbd/documents/UDC7(1).pdf Accessed January 3, 2009
58. Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost 2010 36 (5) 485-492
59. Giannelli F, Green P M., Sommer S S. et al. Haemophilia B: database of point mutations and short additions and deletionseighth edition. Nucleic Acids Res 1998 26 (1) 265-268
60. Gomperts E D., Lee M, Nichols T, Griffith M. IB1001, a new recombinant factor IX preparation: Initial safety and characterization. J Thromb Haemost 2007 5 Abstract OC-MO-086
61. Van Cott K E., Monahan P E., Nichols T C., Velander W H. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide. Haemophilia 2004 10 (suppl 4) 70-76
62. Pollock D P., Kutzko J P., Birck-Wilson E, Williams J L., Echelard Y, Meade H M. Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods 1999 231 (1-2) 147-157
63. Schnieke A E., Kind A J., Ritchie W A. et al. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 1997 278 (5346) 2130-2133
64. Lindsay M, Gil G C., Cadiz A, Velander W H., Zhang C, Van Cott K E. Purification of recombinant DNA-derived factor IX produced in transgenic pig milk and fractionation of active and inactive subpopulations. J Chromatogr A 2004 1026 (1-2) 149-157
65. Gil G C., Velander W H., Van Cott K E. Analysis of the N-glycans of recombinant human factor IX purified from transgenic pig milk. Glycobiology 2008 18 (7) 526-539
66. Roopenian D C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007 7 (9) 715-725
67. Bitonti A J., Dumont J A., Low S C. et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A 2004 101 (26) 9763-9768
68. Peters R T., Low S C., Kamphaus G D. et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010 115 (10) 2057-2064
69. Sheffield W P., Mamdani A, Hortelano G et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004 126 (4) 565-573
70. Metzner H J., Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009 102 (4) 634-644
71. Elm T, Oestergaard H, Tranholm M. Dose response and prolonged effect of 40K PEG-FIX on bleeding in hemophilia B mice. J Thromb Haemost 2009 7 Abstract OC-MO-084
72. Holm P K., Petersen L C., Bjelke J R. et al. Prolonged in vivo half-life and retained activity of factor IX glycoPEGylated in the activation peptide. J Thromb Haemost 2009 7 Abstract PP-MO-575
73. Murphy S L., High K A. Gene therapy for haemophilia. Br J Haematol 2008 140 (5) 479-487
74. Niemeyer G P., Herzog R W., Mount J et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009 113 (4) 797-806
75. Galeffi P, Brownlee G G. The propeptide region of clotting factor IX is a signal for a vitamin K dependent carboxylase: evidence from protein engineering of amino acid -4. Nucleic Acids Res 1987 15 (22) 9505-9513
76. Handford P A., Winship P R., Brownlee G G. Protein engineering of the propeptide of human factor IX. Protein Eng 1991 4 (3) 319-323
77. Yang X, Walsh P N. An ordered sequential mechanism for factor IX and factor IXa binding to platelet receptors in the assembly of the factor X-activating complex. Biochem J 2005 390 (Pt 1) 157-167
78. Cheung W F., Straight D L., Smith K J., Lin S W., Roberts H R., Stafford D W. The role of the epidermal growth factor-1 and hydrophobic stack domains of human factor IX in binding to endothelial cells. J Biol Chem 1991 266 (14) 8797-8800
79. Rees D J., Jones I M., Handford P A. et al. The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX. EMBO J 1988 7 (7) 2053-2061
80. Lenting P J., Christophe O D., Maat H, Rees D J., Mertens K. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem 1996 271 (41) 25332-25337
81. Mathur A, Bajaj S P. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem 1999 274 (26) 18477-18486
82. Lin S W., Smith K J., Welsch D, Stafford D W. Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells. J Biol Chem 1990 265 (1) 144-150
83. Zhong D, Smith K J., Birktoft J J., Bajaj S P. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natl Acad Sci U S A 1994 91 (9) 3574-3578
84. Chang Y J., Wu H L., Hamaguchi N, Hsu Y C., Lin S W. Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa. J Biol Chem 2002 277 (28) 25393-25399
85. Chang J, Jin J, Lollar P et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998 273 (20) 12089-12094
86. Simioni P, Tormene D, Tognin G et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009 361 (17) 1671-1675
87. Finn J D., Simioni P, Iacobelli N et al. FIX-R338L (FIX Padua) as a successful alternative for the treatment of canine severe hemophilia B. Blood 2009 114 290-291. Abstract 694
88. Ewenstein B M., Joist J H., Shapiro A D. et al, Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002 42 (2) 190-197
89. Kisker C T., Eisberg A, Schwartz B, Mononine Study Group. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003 9 (3) 279-284
90. Martorell M, Altisent C, Parra R. Recovery of recombinant factor IX determined in clinical practice. Haemophilia 2009 15 (3) 840-842